Emergency Alert!
 |
 |
FDA’s New Sneak Attack on Supplements
FDA’s New Sneak Attack on Supplements
On July 1, the US Food and Drug Administration issued draft guidance for complying
with the New Dietary Ingredient (NDI) notification protocols contained in the
Dietary Supplement Health and Education Act (DSHEA).
Ever since DSHEA was enacted in 1994, supplement manufacturers have had very
little guidance on what counts as an NDI and when or how to send an NDI
notification. The government has arbitrarily ignored or enforced this section of
DSHEA, doing as it liked, without spelling out the rules.
Why does this matter? Because when you hear New Dietary Ingredient (NDI),
substitute “New Supplement” in your mind. What we are dealing with here is
whether the supplement industry is allowed to innovate and create new
supplements—and if so, under what rules.
Now, seventeen years after the passage of DSHEA, the FDA has finally come out
with draft guidance on NDIs—that is, on new supplements. They had to do this
because it was mandated by the recent Food Safety Modernization Act.
We have reviewed the very complicated new regulations in detail.
In the hands of an agency charged with regulating supplements fairly—one not
hostile to supplements the way FDA is—they might be made to work.
But in the hands of the FDA, which wants everything, supplements and drugs alike,
to go through the vastly expensive new drug approval process, we fear the new
rules will be used to forbid the development or sale of any new supplements—
where “new” means anything after 1994, when DSHEA was passed.
Please note that many important supplements sold today were developed after
1994. Others the FDA will say were developed after 1994, even though they are just
variants of what was “grandfathered” by DSHEA.
For example, the FDA has already banned a critical form of vitamin B6,
pyridoxamine, because that particular form of B6 couldn’t be shown to have been
sold prior to 1994, even though B6 in general was certainly sold prior to 1994.
There are many other important new supplements that could be banned depending
on how the NDI process is run.
We won’t mention the names because to do so would be to put a target on their
back. But we can assure you they are important and many of you are taking them.
The FDA already has the power to pull from the market any supplement, whether
“grandfathered” or not, if they are unsafe, do not comply with Good Manufacturing
Practices, etc. The oft-repeated claim that the supplements market is unregulated
or “the Wild West” is patently false.
But the FDA cannot pull a grandfathered supplement arbitrarily. They must show
cause. What we don’t want is for the FDA to have the power to ban all new
supplements arbitrarily. We fear that they will use this power to ban any
supplement innovation unless the supplement is turned into a drug and brought
through the drug approval process.
Since nobody can afford to pay for the new drug approval process if the substance
is not patented, and supplements generally already exist in nature and cannot
therefore be patented, to require full new drug approval is to ensure that there will
be no new supplements. This should suit the drug industry very well and, based on
past behavior, the FDA as well.
Our Concerns with the New Draft Guidance
The draft guidance clearly outlines the conditions under which an ingredient is
considered an NDI (a new supplement) and when it is considered grandfathered.
Further, it details the circumstances under which it is necessary to submit a
notification for an NDI and when it is not. Not surprisingly, the FDA has applied a
very narrow definition of grandfathered dietary ingredients, and so by extension a
very broad definition of NDI.
Consequently, according to the draft guidance, almost all new supplements are NDIs,
and thus are subject to NDI notification.
Please look carefully at this word “notification.” The term implies that the
supplement company is just telling the FDA about the new product. But this is not
the case. It is actually an approval process, and the FDA turns down most NDI
applications.
Under the new rules, all ingredients/supplements in the food supply before 1994
that have been chemically altered in any way are considered NDIs and therefore
subject to NDI notification. Moreover, the definition of “chemically altered” is
extremely broad, describing multiple manufacturing processes that include:
•certain types of fermentation (probiotics)
•exposing ingredients to high temperature baking and cooking (if such treatment is
not usually applied to the ingredient in conventional food)
•use of a botanical ingredient at a different life stage than previously used—for
example, an extract of unripe apples instead of ripe apples
So if the ingredient is not absolutely identical to its pre-1994 counterpart, then it is
considered an NDI and subject to NDI notification/approval.
Drug companies can exploit this process by trying to patent common dietary
ingredients as drugs before supplement companies have an opportunity to submit
their NDI notifications.
Once a drug company investigates an ingredient for drug purposes and publishes
their findings, the ingredient can no longer be used in supplements.
This has happened before—it happened with the pyridoxamine form of vitamin B6
we mentioned above. In other words, what was once a supplement available to
consumers at low cost will now be an expensive prescription-only drug, if it is
available at all.
(And it’s not only the drug that costs more: you’ll need to pay your doctor for
an office visit just to get the prescription!)
The draft guidance also states that a synthetic copy of a supplement constituent, or
an extract of an herb or other botanical, is not considered a dietary ingredient at all
(much less an NDI). Isn’t this good—isn’t it better not to be an NDI?
No. If the FDA says it is not an NDI, that means they are saying it can only be sold as
a drug—period. This could knock out a number of important supplements currently
sold.
The guidance discusses at length the evidence required for a notification (approval)
—and the requirements are extensive, including a strong recommendation to include
human studies.
We sometimes forget that human studies, in addition to being very costly, do not
always fit supplements.
In effect, it appears that the draft guidance pushes the scientific standard for NDI
notifications closer and closer to the pharmaceutical standard.
As we have mentioned many times before, supplements are much safer than drugs,
yet because of the big Catch-22 (supplements cannot usually be patented, and no
non-patentable substance can be taken through a drug approval process which, on
average, costs a billion dollars), it is very difficult for supplement manufactures to
meet these standards.
If they are met, it will push the price of supplements—already high—beyond
consumers’ reach. The industry will die.
In these proposed rules, the FDA has effectively created a de facto pre-market
approval system without any of the protections of such a system.
The FDA has a very high bar that a supplement manufacturer must reach before
they can file, but FDA reserves the right to reverse its decision about the safety of
an ingredient at any time. It is important for the FDA to recognize the NDI process
was meant by Congress to be an actual notification system, not a pre-approval
process run according to arbitrary rules set up by the FDA.
Congress gave the FDA power to say no, but this was expected to be rare, while
the FDA currently vetoes more often than not, often on trivial grounds.
In general, the draft guidance creates a process that is extremely burdensome and
redundant—and is impossible for the FDA to realistically implement anyway.
The FDA even makes the NDI notification specific to the manufacturer, not the
ingredient.
So if two manufacturers are marketing the same ingredient, at the same quantity—
they still each have to submit an NDI notification. They can’t hire a third party to
do it for them as a group. This is arbitrary and punitive—there is no reason for this
requirement at all.
The FDA also expects a different notification for the same ingredient for every
different version of the supplement it is in. For example, the same ingredient at a
higher concentration needs a separate notification/approval. Or the same
ingredient in a different combination of ingredients requires yet another
notification/approval.
The bottom line is that when new and unreasonable burdens are placed on
supplement manufacturers, it immediately becomes a financial increase for
consumers. And if the pressure becomes too great, the nutritional supplements on
which you rely may simply become unavailable.
Please contact the FDA immediately and voice your strong opposition to the New
Dietary Ingredient draft guidance!
Here is a wonderful link:
Click here:
Please be heard
FDA’s New Sneak Attack on Supplements
On July 1, the US Food and Drug Administration issued draft guidance for complying
with the New Dietary Ingredient (NDI) notification protocols contained in the
Dietary Supplement Health and Education Act (DSHEA).
Ever since DSHEA was enacted in 1994, supplement manufacturers have had very
little guidance on what counts as an NDI and when or how to send an NDI
notification. The government has arbitrarily ignored or enforced this section of
DSHEA, doing as it liked, without spelling out the rules.
Why does this matter? Because when you hear New Dietary Ingredient (NDI),
substitute “New Supplement” in your mind. What we are dealing with here is
whether the supplement industry is allowed to innovate and create new
supplements—and if so, under what rules.
Now, seventeen years after the passage of DSHEA, the FDA has finally come out
with draft guidance on NDIs—that is, on new supplements. They had to do this
because it was mandated by the recent Food Safety Modernization Act.
We have reviewed the very complicated new regulations in detail.
In the hands of an agency charged with regulating supplements fairly—one not
hostile to supplements the way FDA is—they might be made to work.
But in the hands of the FDA, which wants everything, supplements and drugs alike,
to go through the vastly expensive new drug approval process, we fear the new
rules will be used to forbid the development or sale of any new supplements—
where “new” means anything after 1994, when DSHEA was passed.
Please note that many important supplements sold today were developed after
1994. Others the FDA will say were developed after 1994, even though they are just
variants of what was “grandfathered” by DSHEA.
For example, the FDA has already banned a critical form of vitamin B6,
pyridoxamine, because that particular form of B6 couldn’t be shown to have been
sold prior to 1994, even though B6 in general was certainly sold prior to 1994.
There are many other important new supplements that could be banned depending
on how the NDI process is run.
We won’t mention the names because to do so would be to put a target on their
back. But we can assure you they are important and many of you are taking them.
The FDA already has the power to pull from the market any supplement, whether
“grandfathered” or not, if they are unsafe, do not comply with Good Manufacturing
Practices, etc. The oft-repeated claim that the supplements market is unregulated
or “the Wild West” is patently false.
But the FDA cannot pull a grandfathered supplement arbitrarily. They must show
cause. What we don’t want is for the FDA to have the power to ban all new
supplements arbitrarily. We fear that they will use this power to ban any
supplement innovation unless the supplement is turned into a drug and brought
through the drug approval process.
Since nobody can afford to pay for the new drug approval process if the substance
is not patented, and supplements generally already exist in nature and cannot
therefore be patented, to require full new drug approval is to ensure that there will
be no new supplements. This should suit the drug industry very well and, based on
past behavior, the FDA as well.
Our Concerns with the New Draft Guidance
The draft guidance clearly outlines the conditions under which an ingredient is
considered an NDI (a new supplement) and when it is considered grandfathered.
Further, it details the circumstances under which it is necessary to submit a
notification for an NDI and when it is not. Not surprisingly, the FDA has applied a
very narrow definition of grandfathered dietary ingredients, and so by extension a
very broad definition of NDI.
Consequently, according to the draft guidance, almost all new supplements are NDIs,
and thus are subject to NDI notification.
Please look carefully at this word “notification.” The term implies that the
supplement company is just telling the FDA about the new product. But this is not
the case. It is actually an approval process, and the FDA turns down most NDI
applications.
Under the new rules, all ingredients/supplements in the food supply before 1994
that have been chemically altered in any way are considered NDIs and therefore
subject to NDI notification. Moreover, the definition of “chemically altered” is
extremely broad, describing multiple manufacturing processes that include:
•certain types of fermentation (probiotics)
•exposing ingredients to high temperature baking and cooking (if such treatment is
not usually applied to the ingredient in conventional food)
•use of a botanical ingredient at a different life stage than previously used—for
example, an extract of unripe apples instead of ripe apples
So if the ingredient is not absolutely identical to its pre-1994 counterpart, then it is
considered an NDI and subject to NDI notification/approval.
Drug companies can exploit this process by trying to patent common dietary
ingredients as drugs before supplement companies have an opportunity to submit
their NDI notifications.
Once a drug company investigates an ingredient for drug purposes and publishes
their findings, the ingredient can no longer be used in supplements.
This has happened before—it happened with the pyridoxamine form of vitamin B6
we mentioned above. In other words, what was once a supplement available to
consumers at low cost will now be an expensive prescription-only drug, if it is
available at all.
(And it’s not only the drug that costs more: you’ll need to pay your doctor for
an office visit just to get the prescription!)
The draft guidance also states that a synthetic copy of a supplement constituent, or
an extract of an herb or other botanical, is not considered a dietary ingredient at all
(much less an NDI). Isn’t this good—isn’t it better not to be an NDI?
No. If the FDA says it is not an NDI, that means they are saying it can only be sold as
a drug—period. This could knock out a number of important supplements currently
sold.
The guidance discusses at length the evidence required for a notification (approval)
—and the requirements are extensive, including a strong recommendation to include
human studies.
We sometimes forget that human studies, in addition to being very costly, do not
always fit supplements.
In effect, it appears that the draft guidance pushes the scientific standard for NDI
notifications closer and closer to the pharmaceutical standard.
As we have mentioned many times before, supplements are much safer than drugs,
yet because of the big Catch-22 (supplements cannot usually be patented, and no
non-patentable substance can be taken through a drug approval process which, on
average, costs a billion dollars), it is very difficult for supplement manufactures to
meet these standards.
If they are met, it will push the price of supplements—already high—beyond
consumers’ reach. The industry will die.
In these proposed rules, the FDA has effectively created a de facto pre-market
approval system without any of the protections of such a system.
The FDA has a very high bar that a supplement manufacturer must reach before
they can file, but FDA reserves the right to reverse its decision about the safety of
an ingredient at any time. It is important for the FDA to recognize the NDI process
was meant by Congress to be an actual notification system, not a pre-approval
process run according to arbitrary rules set up by the FDA.
Congress gave the FDA power to say no, but this was expected to be rare, while
the FDA currently vetoes more often than not, often on trivial grounds.
In general, the draft guidance creates a process that is extremely burdensome and
redundant—and is impossible for the FDA to realistically implement anyway.
The FDA even makes the NDI notification specific to the manufacturer, not the
ingredient.
So if two manufacturers are marketing the same ingredient, at the same quantity—
they still each have to submit an NDI notification. They can’t hire a third party to
do it for them as a group. This is arbitrary and punitive—there is no reason for this
requirement at all.
The FDA also expects a different notification for the same ingredient for every
different version of the supplement it is in. For example, the same ingredient at a
higher concentration needs a separate notification/approval. Or the same
ingredient in a different combination of ingredients requires yet another
notification/approval.
The bottom line is that when new and unreasonable burdens are placed on
supplement manufacturers, it immediately becomes a financial increase for
consumers. And if the pressure becomes too great, the nutritional supplements on
which you rely may simply become unavailable.
Please contact the FDA immediately and voice your strong opposition to the New
Dietary Ingredient draft guidance!
Here is a wonderful link:
Click here:
Please be heard